Candel Therapeutics, Inc. CADL 深 沪
交易中 06-24 09:47:18 美东时间
9.07
-0.010
-0.11%
华盛通- 最 高9.13
- 今 开9.08
- 成交量 1.39万股
- 最 低 9.07
- 昨 收 9.08
- 总市值 6.65亿
- 52周最高 9.5699
- 市盈率 静 --
- 换手率 0.02%
- 52周最低 4.35
- 委 比 92.34%
- 总股本 7327.02万
- 历史最高 14.78
- 量 比 0.90
- 振 幅 0.66%
- 历史最低 0.66
- 每 手 1
- 风险率 1.13%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Candel Therapeutics Announces Lancet Oncology Publication Of Phase 3 Data Showing 30% DFS Improvement For Aglatimagene Besadenovec In Localized Prostate Cancer
Peer reviewed publication details pivotal data, demonstrating 30% improvement in disease-free survival (DFS) in patients with localized prostate cancer undergoing standard-of-care radiotherapy with curative intent
06-02 20:19
Candel Therapeutics Presents New Results From Extended Follow-Up Of Randomized, Double-Blind, Placebo-Controlled Pivotal Phase 3 Trial Of Aglatimagene Besadenovec In Prostate Cancer At AUA 2026 Annual Meeting
Extended follow-up data from the phase 3 study (20 months after reported topline data, median follow-up 58 months) confirmed a statistically significant and clinically meaningful improvement in prostate cancer–specific
05-16 04:07
Candel Therapeutics Q1 EPS $(0.14) Beats $(0.34) Estimate
Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.34) by 58.82 percent. This is a 207.69 percent decrease over earnings of $0.13 per share
05-14 20:12
Candel Therapeutics To Hold Conference Call On May 15 To Discuss Extended Follow-Up Data From Its Phase 3 Clinical Study Of Aglatimagene Besadenovec In Participants With Intermediate- To High-Risk Localized Prostate Cancer
Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for patients with cancer, today announced
05-04 20:17
Cantor Fitzgerald Initiates Coverage On Candel Therapeutics with Overweight Rating
Cantor Fitzgerald initiates coverage on Candel Therapeutics (NASDAQ:CADL) with a Overweight rating.
04-20 23:08
10 Health Care Stocks Moving In Friday's Intraday Session
Gainers Psyence Biomedical (NASDAQ:PBM) shares increased by 40.5% to $8.25 dur...
04-18 01:05
美股大行评级 | 超多下调！露露乐蒙、Oklo、腾讯音乐、Docusign、BOBS、Bicycle、Academy Sports等遭多家大行下调目标价
今日重点评级关注：花旗：维持Candel Therapeutics"买入"评级，目标价从22美元升至26美元；Chardan Capital：维持CervoMed"买入"评级，目标价从15美元升至21美元
03-19 14:31
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Non-Small Cell Lung Cancer Treatment
Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with advanced non-small cell lung cancer (NSCLC) treated with aglatimagene
03-17 20:12
美股大行评级 | 韦德布什升美光科技目标价升至500美元，维持"跑赢大市"评级
今日重点评级关注：Piper Sandler：维持Allogene疗法"超配"评级，目标价从7美元升至8美元；B. Riley证券：维持Oncology Institute"买入"评级，目标价从6美元升至8美元
03-16 18:19
Candel Therapeutics Q4 EPS $(0.54) Misses $(0.24) Estimate
Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.24) by 120.41 percent. This is a 35 percent decrease over losses of $(0.40) per share
03-12 20:25
